Publikationen

Auf dieser Seite können Sie die aktuellen Publikationen einsehen, die im Rahmen der KFO 227 entstanden sind bzw. zukünftig entstehen werden.

2017

Rahbari NN*. Schölch S*, Bork U, Kahlert C, Schneider M, Rahbari M, Büchler MW, Weitz J, Reißfelder C. Prognostic value of circulating endothelial cells in metastatic colorectal cancer. Oncotarget 2017 [in press]

Dieter SM*, Giessler KM*, Kriegsmann M, Dubash TD, Möhrmann L, Schulz E, Siegl C, Weber S, Strakerjahn H, Oberlack A, Heger U, Gao J, Hartinger EM, Oppel F, Hoffmann CM, Ha N, Brors B, Lasitschka F, Ulrich A, Strobel O, Schneider M, Weichert W, Ehrenberg KR, Glimm H#, Ball CR#. Patient-derived Xenografts of Gastrointestinal Cancers Are Susceptible to Rapid and Delayed B-Lymphoproliferation. Int. J. Cancer. 2017 Mar 15;140(6):1356-1363. doi: 10.1002/ijc.30561.

Weischenfeldt J*, Dubash TDD*, Drainas AP*, Mardin BR, Chen Y, Stütz AM, Waszak SM, Bosco G, Halvorsen AR, Raeder B, Efthymiopoulos T, Brenner H, Brustugun OT, Dieter SM, Northcott P, Petersen I, Pfister S, Schneider M, Solberg SK, Thunissen E, Weichert W, Zichner T, Thomas R, Peifer M, Helland A, Ball CR, Jechlinger M, Sotillo R, Glimm H# & Korbel JO#. Pan-cancer analysis implicates IRS4 and IGF2 in enhancer hijacking. Nat Genet. 2017 Jan;49(1):65-74. doi: 10.1038/ng.3722

2016

Scherr AL, Gdynia G, Salou M, Radhakrishnan P, Duglova K, Heller A, Keim S, Kautz N, Jassowicz A, Elssner C, He YW, Jaeger D, Heikenwalder M, Schneider M, Weber A, Roth W, Schulze-Bergkamen H, Koehler BC. Bcl-xL is an oncogenic driver in colorectal cancer. Cell Death Dis. 2016 Aug 18;7(8):e2342. doi: 10.1038/cddis.2016.233.

Koehler BC, Arslic-Schmitt T, Peccerella T, Scherr AL, Schulze-Bergkamen H, Bruckner T, Gdynia G, Jäger D, Mueller S, Bartsch H, Seitz HK. Possible Mechanisms of Ethanol-Mediated Colorectal Carcinogenesis: The Role of Cytochrome P4502E1, Etheno-DNA Adducts, and the Anti-Apoptotic Protein Mcl-1. Alcohol Clin Exp Res. 2016 Oct;40(10):2094-2101. doi: 10.1111/acer.13180.

Weiss J, Gajek T, Köhler BC, Haefeli WE. Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug-Drug Interactions.Pharmaceutics. 2016 Feb 24;8(1). pii: E5. doi: 10.3390/pharmaceutics8010005.

Radhakrishnan P, Ruh N, Harnoss JM, Kiss J, Mollenhauer M, Scherr AL, Platzer LK, Schmidt T, Podar K, Opferman JT, Weitz J, Schulze-Bergkamen H, Koehler BC, Ulrich A, Schneider M. Prolyl Hydroxylase 3 Attenuates MCL-1-Mediated ATP Production to Suppress the Metastatic Potential of Colorectal Cancer Cells.Cancer Res. 2016 Apr 15;76(8):2219-30. doi: 10.1158/0008-5472.CAN-15-1474.

Ahadova A, von Knebel Doeberitz M, Bläker H, Kloor M. CTNNB1-mutant colorectal carcinomas with immediate invasive growth: a model of interval cancers in Lynch syndrome. Fam Cancer. 2016 Oct;15(4):579-86.

Kloor M, von Knebel Doeberitz M. The immune biology of microsatellite-unstable cancer. Trends in Cancer. 2016 Mar;2(3):121-133.

Klupp F, Neumann L, Kahlert C, Diers J, Halama N, Franz C, Schmidt T, Koch M, Weitz J, Schneider M, Ulrich A. Serum MMP7, MMP10 and MMP12 level as negative prognostic markers in colon cancer patients. BMC Cancer. 2016 Jul 18;16(1):494. doi: 10.1186/s12885-016-2515-7.

Rogers MA, Kalter V, Marcias G, Zapatka M, Barbus S, Lichter P. CITED4 gene silencing in colorectal cancer cells modulates adherens / tight junction gene expression and reduces cell proliferation. J Cancer Res Clin Oncol. 2016; 142: 225–237.

Rogers MA, Kalter V, Strowitzki M, Schneider M, Lichter P. IGF2 knockdown in two colorectal cancer cell lines decreases survival, adhesion and modulates survival-associated genes. Tumour Biol. 2016 2016 Sep;37(9):12485-12495. Epub 2016 Jun 23.

Halama N, Zoernig I, Berthel A, Kahlert C, Klupp F, Suarez-Carmona M, Suetterlin T, Brand K, Krauss J, Lasitschka F, Lerchl T, Luckner-Minden C, Ulrich A, Koch M, Weitz J, Schneider M, Buechler MW, Zitvogel L, Herrmann T, Benner A, Kunz C, Luecke S, Springfeld C, Grabe N, Falk CS, Jaeger D. Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients. Cancer Cell. 2016 Apr 11;29(4):587-601. doi: 10.1016/j.ccell.2016.03.005.

Dubash TD, Hoffmann CM, Oppel F, Giessler KM, Weber S, Dieter SM, Hüllein J, Zenz T, Herbst F, Scholl C, Weichert W, Werft W, Benner A, Schmidt M, Schneider M, Glimm H, Ball CR. Phenotypic differentiation does not affect tumorigenicity of primary human colon cancer initiating cells. Cancer Lett. 2016 Feb 28;371(2):326-33. doi: 10.1016/j.canlet.2015.11.037.

Schölch S*, García S*, Iwata N*, Niemietz T, Betzler A, Nanduri LK, Bork U, Kahlert C, Thepkaysone M, Swiersy A, Büchler MW, Reissfelder C, Weitz J, Rahbari NN. Circulating tumor cells exhibit stem cell characteristics in an orthotopic mouse model of colorectal cancer. Oncotarget 2016 2016 Mar 25. doi: 10.18632/oncotarget.8373. [Epub ahead of print]

Rahbari NN*, Bork U*, Schölch S*, Reissfelder C, Thorlund K, Betzler AM, Kahlert C, Schneider M, Ulrich AB, Büchler MW,  Weitz J*, Koch M*. Metastatic Spread Emerging from Liver Metastases of Colorectal Cancer - Does the Seed Leave the Soil Again? Ann Surg 2016;263(2):345–52 

2015

Klupp F, Diers J, Kahlert C, Neumann L, Halama N, Franz C, Schmidt T, Lasitschka F, Warth A, Weitz J, Koch M, Schneider M, Ulrich A. Expressional STAT3/STAT5 Ratio is an Independent Prognostic Marker in Colon Carcinoma. Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1548-55. doi: 10.1245/s10434-015-4485-4. Epub 2015 Mar 13.

Koehler BC, Jassowicz A, Scherr AL, Lorenz S, Radhakrishnan P, Kautz N, Elssner C, Weiss J, Jaeger D, Schneider M, Schulze-Bergkamen H. Pan-Bcl-2 inhibitor Obatoclax is a potent late stage autophagy inhibitor in colorectal cancer cells independent of canonical autophagy signaling. BMC Cancer. 2015 Nov 19;15(1):919. doi: 10.1186/s12885-015-1929-y.

Schölch S*, Rauber C*, Tietz A, Rahbari NN, Bork U, Schmidt T, Kahlert C, Haberkorn U, Tomai MA, Lipson KE, Carretero R, Weitz J, Koch M*, Huber PE*. Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors. Oncotarget 2015;6:4663-76

Rogers MA, Kalter V, Marcias G, Zapataka M, Barbus S, Lichter P. CITED4 gene silencing in colorectal cancer cells modulates adherens/tight junction gene expression and reduces cell proliferation. J. Cancer Res. Clin. Oncol. 2015. June 27; DOI 10.1007/s00432-015-2011-5.

Bork U, Rahbari NN, Schölch S, Reissfelder C, Kahlert C, Büchler MW, Weitz J, Koch M. Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study. British Journal of Cancer (2015) 112, 1306-1313.

Harnoss JM, Strowitzki M, Radhakrishnan P, Platzer L, Harnoss JC, Hank T, Cai J, Ulrich A, Schneider M. Therapeutic Inhibition of prolyl hydroxylase domain-containing enzymes in surgery: putative applications and challenges. Hypoxia (invited review), 3:1-14 (2015).

2014

Schölch S, Rauber C, Tietz A, Rahbari NN, Bork U, Schmidt T, Kahlert C, Haberkorn U, Tomai MA, Lipson KE, Carretero R, Weitz J, Koch M, Huber PE. Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors. Oncotarget. 2014 Dec 31.

Koehler BC, Scherr AL, Lorenz S, Elssner C, Kautz N, Welte S, Jaeger D, Urbanik T, Schulze-Bergkamen H. Pan-bcl-2 inhibitor obatoclax delays cell cycle progression and blocks migration of colorectal cancer cells. PLoS One. 2014 Sep 5;9(9):e106571.doi:10.1371/journal.pone. 0106571.eCollection 2014.

Steinert G, Schölch S, Niemietz T, Iwata N, Garcia S, Behrens B, Voigt A, Kloor M, Benner A, Bork U,Rahbari NN, Büchler MW, Stoecklein N, Weitz J, Koch M. Immune Escape and Survival Mechanisms in Circulating Tumor Cells of Colorectal Cancer. Cancer Res. 2014;74(6):1694-1704.

Koehler BC, Jäger D, Schulze-Bergkamen H. Targeting cell death signaling in colorectal cancer: current strategies and future perspectives. World J Gastroenterol. 2014 Feb 28;20(8):1923-34. doi: 10.3748/wjg.v20.i8.1923.

2013

Capper D, Voigt A, Bozukova G, Ahadova A, Kickingereder P, von Deimling A, von Knebel Doeberitz M, Kloor M. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. Int J Cancer. 2013 Oct 1;133(7):1624-30. doi: 10.1002/ijc.28183. Epub 2013 Apr 25.

Sherwood AM, Emerson RO, Scherer D, Habermann N, Buck K, Staffa J, Desmarais C, Halama N, Jaeger D, Schirmacher P, Herpel E, Kloor M, Ulrich A, Schneider M, Ulrich CM, Robins H. Tumor-infiltrating lymphocytes in colorectal tumors display a diversity of T cell receptor sequences that differ from the T cells in adjacent mucosal tissue. Cancer Immunol Immunother. 2013 Sep;62(9):1453-61.

Voloshanenko O, Erdmann G, Dubash TD, Augustin I, Metzig M, Moffa G, Hundsrucker C, Kerr G, Sandmann T, Anchang B, Demir K, Boehm C, Leible S, Ball CR, Glimm H, Spang R, Boutros M. Wnt secretion is required to maintain high levels of Wnt activity in colon cancer cells. Nat Commun 2013;4:2610. doi: 10.1038/ncomms3610.

Koehler BC, Scherr AL, Lorenz S, Urbanik T, Kautz N, Elssner C, Welte S, Bermejo JL, Jäger D, Schulze-Bergkamen H. Beyond Cell Death - Antiapoptotic Bcl-2 Proteins Regulate Migration and Invasion of Colorectal Cancer Cells In Vitro. PLoS One. 2013 Oct 3;8(10):e76446.

Lee J, Ballikaya S, Schönig K, Ball CR, Glimm H, Kopitz J, Gebert J. Transforming Growth Factor Beta Receptor 2 (TGFBR2) Changes Sialylation in the Microsatellite Unstable (MSI) Colorectal Cancer Cell Line HCT116. PLoS One. 2013;8(2):e57074. doi: 10.1371/journal.pone.0057074. Epub 2013 Feb 27.

Bach P, Abel T, Hoffmann C, Gal Z, Braun G, Voelker I, Ball CR, Johnston IC, Lauer UM, Herold-Mende C, Mühlebach MD, Glimm H, Buchholz CJ. Specific Elimination of CD133+ Tumor Cells with Targeted Oncolytic Measles Virus. Cancer Res. 2013 Jan 15;73(2):865-74. doi: 10.1158/0008-5472.CAN-12-2221. Epub 2013 Jan 4.

Azoitei N, Hoffmann CM, Ellegast JM, Ball CR, Obermayer K, Gößele U, Koch B, Faber K, Genze F, Schrader M, Kestler HA, Döhner H, Chiosis G, Glimm H, Fröhling S, Scholl C. Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33. J Exp Med 2012; 209(4):697-711.

Halama N, Spille A, Lerchl T, Brand K, Herpel E, Welte S, Keim S, Lahrmann B, Klupp F, Kahlert C, Weitz J, Grabe N, Jaeger D, Zoernig I. Hepatic metastases of colorectal cancer are rather homogeneous but differ from primary lesions in terms of immune cell infiltration. Oncoimmunology 2013 Apr 1;2(4):e24116.

2012

Rahbari NN, Bork U, Niemietz T, Schölch S, Steinert G, Kircher A, Büchler MW, Koch M, Weitz J. Compartmental differences of circulating tumor cells in colorectal cancer. Annals of Surgical Oncology 2012 Jul;19(7):2195-202. doi: 10.1245/s10434-011-2178-1. Epub 2012 Jan 10.

Huth M, Kloor M, Voigt A, Bozukova G, Evers C, Gaspar H, Tariverdian M, Schirmacher P, von Knebel Doeberitz M, Blaeker H. The molecular basis of EPCAM expression loss in Lynch syndrome-associated tumors. Mod Pathol 2012 Jun;25(6):911-6. doi: 10.1038/modpathol. 2012.30. Epub 2012 Mar 2.

Kiss J, Mollenhauer M, Walmsley S, Kirchberg J, Radhakrishnan P, Niemietz T, Dudda J, Steinert G, Whyte M, Carmeliet P, Mazzone M, Weitz J, Schneider M. Loss of the Poxygen Sensor PHD3 Enhances the Innate Immune Response to Abdominal Sepsis. J Immunol 2012 Aug 15;189(4):1955-65. Epub 2012 Jul 11. 

Tikidzhieva A, Benner A, Michel S, Formentini A, Link KH, Dippold W, von Knebel Doeberitz M, Kornmann M, Kloor M. Microsatellite instability and Beta2-Microglobulin mutations as prognostic markers in colorectal cancer: results of the FOGT4-trial. Br J Cancer. 2012 Mar 13;106(6):1239-45. doi: 10.1038/bjc.2012.53. Epub 2012 Feb 21.

Bauer K, Nelius N, Reuschenbach M, Koch M, Weitz J, Steinert G, Kopitz J, Beckhove P, Tariverdian M, von Knebel Doeberitz M, Kloor M. T cell responses against microsatellite instability-induced frameshift peptides and influence of regulatory T cells in colorectal cancer. Cancer Immunol Immunother 2013 Jan;62(1):27-37. doi: 10.1007/s00262-012-1303-8. Epub 2012 Jun 23.

Kloor M, Huth C, Voigt A, Benner A, Schirmacher P, von Knebel Doeberitz M, Blaeker H. Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study. Lancet Oncology 2012 Jun;13(6):598-606. Epub 2012 May 1.

Azoitei N, Hoffmann CM, Ellegast JM, Ball CR, Obermayer K, Gößele U, Koch B, Faber K, Genze F, Schrader M, Kestler HA, Döhner H, Chiosis G, Glimm H, Fröhling S, Scholl C. Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33. J Exp Med 2012 Apr 9;209(4):697-711. Epub 2012 Mar 26.

Bandapalli OR, Macher-Goeppinger S, Schirmacher P, Brand K. Paracrine signalling in colorectal liver metastases involving tumor cell-derived PDGF-C and hepatic stellate cell-derived PAK-2. Clin Exp Metastasis 2012 Jun;29(5):409-17. Epub 2012 Feb 24.

2011

Walmsley SR, Chilvers ER, Thompson AA, Vaughan K, Marriott HM, Parker LC, Shaw G, Parmar S, Schneider M, Sabroe I, Dockrell DH, Milo M, Taylor CT, Johnson RS, Pugh CW, Ratcliffe PJ, Maxwell PH, Carmeliet P and Whyte MK. Prolyl hydroxylase PHD3 is essential for hypoxic regulation of neutrophilic inflammation in humans and mice.  J Clin Invest 2011 Mar 1;121(3):1053-63. doi: 10.1172/JCI43273. Epub 2011 Feb 7.

Rahbari NN, Bork U, Motschall E, Thorlund K, Büchler MW, Koch M, Weitz J. Molecular Detection of Tumor Cells in Regional Lymph Nodes Is Associated With Disease Recurrence and Poor Survival in Node-Negative Colorectal Cancer: A Systematic Review and Meta-Analysis. J Clin Oncol 2012 Jan 1;30(1):60-70. Epub 2011 Nov 28.

Ernst A, Aigner M, Nakata S, Engel F, Schlotter M, Kloor M, Brand K, Schmitt S, Steinert G, Rahbari N, Koch M, Radlwimmer B, Weitz J, Lichter P (2011). A gene signature distinguishing CD133(hi) from CD133(-) colorectal cancer cells: essential role for EGR1 and downstream factors. Pathology 2011 Apr;43(3): 220-227.

Rahbari NN, Reissfelder C, Mühlbayer M, Weidmann K, Kahlert K, Büchler MW, Weitz J, Koch M. Correlation of circulating angiogenic factors with circulating tumor cells and disease recurrence in patients undergoing curative resection for colorectal liver metastases. Ann Surg Oncol 2011 Aug;18(8):2182-91. Epub 2011 May 20.

Dieter SM, Ball CR, Hoffmann CM, Nowrouzi A, Herbst F, Zavidij O,  Abel U, Arens A, Weichert  W,  Brand K, Koch M,  Weitz J,  Schmidt M,  v. Kalle C & Glimm H. Distinct types of tumor initiating cells form human colon cancer tumors and metastases. Cell Stem Cell 2011 Oct 4;9(4):357-65. doi: 10.1016/j.stem.2011.08.010.

Bauer K, Michel S, Reuschenbach M, Nelius N, von Knebel Doeberitz M, Kloor M. Dendritic cell and macrophage infiltration in microsatellite-unstable and microsatellite-stable colorectal cancer. Fam Cancer 2011 Sep;10(3):557-65.

Kloor M, Voigt AY, Schackert HK, Schirmacher P, von Knebel Doeberitz M, Bläker H. Analysis of EPCAM proteine xpression in diagnosticsof Lynch syndrome. J Clin Oncol 2011 Jan 10;29(2):223-7. Epub 2010 Nov 29.

Reissfelder C, Timke C, Schmitz-Winnenthal H, Rahbari NN, Koch M, Klug F, Roeder F, Edler L, Debus J, Büchler MW, Beckhove P, Huber PE, Weitz J. A randomized controlled trial to investigate the influence of low dose radiotherapy on immune stimulatory effects in liver metastases of colorectal cancer. BMC Cancer 2011 Sep 30;11:419.

Halama N, Michel S, Kloor M, Zoernig I, Benner A, Spille A, Pommerencke T, von Knebel DM, Folprecht G, Luber B, Feyen N, Martens UM, Beckhove P, Gnjatic S, Schirmacher P, Herpel E, Weitz J, Grabe N, Jaeger D. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res 2011 Sep 1;71(17):5670-7. Epub 2011 Aug 16.

Khazaie K, Blatner NR, Khan MW, Gounari F, Gounaris E, Dennis K, Bonertz A, Tsai FN, Strouch MJ, Cheon E, Phillips JD, Beckhove P, Bentrem DJ. The significant role of mast cells in cancer. Cancer Metastasis Rev 2011 Mar;30(1):45-60. Review.

Timke C, Winnenthal HS, Klug F, Roeder FF, Bonertz A, Reissfelder C, Rochet N, Koch M, Tjaden C, Buechler MW, Debus J, Werner J, Beckhove P, Weitz J, Huber PE. Randomized controlled phase I/II study to investigate immune stimulatory effects by low dose radiotherapy in primarily operable pancreatic cancer. BMC Cancer 2011 Apr 13;11:134.

Halama N, Braun M, Kahlert C, Spille A, Quack C, Rahbari N, Koch M, Weitz J, Kloor M, Zoernig I, Schirmacher P, Brand K, Grabe N, Falk CS. Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines.  Clin Cancer Res 2011 Feb 15;17(4):678-89.

Bandapalli OR, Hariri N, Macher-Göppinger S, Kahlert C,  Schirmacher P,  Brand K. Increased Apoptosis of Host Cells and Tumor Cells in the Invasion Front of Colorectal Liver Metastases. Anticancer Research 2011 Apr;31(4):1215-24.

Kahlert C, Klupp F, Brand K, Lasitschka F, Diederichs S, Kirchberg J, Rahbari N, Dutta S, Bork U, Fritzmann J, Reissfelder C, Koch M, Weitz J. Invasion front-specific expression and prognostic significance of microRNA in colorectal liver metastases. Cancer Sci 2011 Oct;102(10):1799-807. Epub 2011 Aug 4 

Kahlert C, Lahes S, Radhakrishnan P, Dutta S, Mogler C, Herpel E, Brand K, Steinert G, Schneider M, Mollenhauer M, Reissfelder C, Klupp F, Fritzmann J, Wunder C, Benner A, Kloor M, Huth C, Contin P, Ulrich A, Koch M, Weitz J. Overexpression of ZEB2 at the Invasion Front of Colorectal Cancer Is an Independent Prognostic Marker and Regulates Tumor Invasion In Vitro. Clin Cancer Res 2011 Dec 15;17(24):7654-63. Epub 2011 Oct 31.

Bandapalli OR, Ehrmann F, Ehemann V, Gaida M, Macher-Goeppinger S, Wente M, Schirmacher P, Brand K. Down-regulation of CXCL1 inhibits tumor growth in colorectal liver metastasis. Cytokine 2012 Jan;57(1):46-53. Epub 2011 Nov 29.

Bandapalli OR, Paul E, Schirmacher P, Brand K. Opposite effects of tissue inhibitor of metalloproteinases- 1 (TIMP-1) over-expression and knockdown on colorectal liver metastases. BMC Res Notes. 2012 Jan 9;5(1):14. [Epub ahead of print]

2010

Rahbari NN, Aigner M, Thorlund K, Mollberg N, Motschall E, Jensen K, Diener MK, Büchler MW, Koch M, Weitz J. Meta-Analysis Shows that Detection of Circulating Tumor Cells Indicates Poor Prognosis in Patients with Colorectal Cancer. Gastroenterology 2010 May;138(5):1714-26. Epub 2010 Jan 25.                               

Antolovic D, Galindo L, Carstens A, Rahbari N, Büchler MW, Weitz J, Koch M. Heterogeneous detection of circulating tumor cells in patients with colorectal cancer by immunomagnetic enrichment using different EpCAM-specific antibodies. BMC Biotechnology 2010 Apr 28;10(1):35. [Epub ahead of print]

Stange DE, Engel F, Longerich T, Koo BK, Koch M, Delhomme N, Aigner M, Toedt G, Schirmacher P, Lichter P, Weitz J, Radlwimmer B. Expression of an ASCL2 related stem cell signature and IGF2 in colorectal cancer liver metastases with 11p15.5 gain. Gut 2010 Sep;59(9):1236-44. Epub 2010 May 17.

Casazza A, Finisguerra V, Capparuccia L, Camperi A, Swiercz JM, Rizzolio S, Rolny C, Christensen C, Bertotti A, Sarotto I, Risio M, Trusolino L, Weitz J, Schneider M, Mazzone M, Comoglio PM and Tamagnone L. Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. J Clin Invest 2010 Aug 2;120(8):2684-98. doi: 10.1172/JCI42118. Epub 2010 Jul 26.

Kloor M, Michel S, von Knebel Doeberitz M. Immune evasion of microsatellite unstable colorectal cancers. Int J Cancer 2010 Sep 1;127(5):1001-10.   

Michel S, Linnebacher M, Alcaniz J, Voss M, Wagner R, Dippold W, Becker C, von Knebel Doeberitz M, Ferrone S, Kloor M. Lack of HLA class II antigen expression in microsatellite unstable colorectal carcinomas is caused by mutations in HLA class II regulatory genes. Int J Cancer 2010 Aug 15;127(4):889-98.

Beckhove P, Warta R, Lemke B, Stoycheva D, Momburg F, Schmitz-Winnenthal H, Ahmadi R, Dyckhoff G, Bucur M, Jünger S, Schoeler T, Lennerz V, Woelfel T, Unterberg A, Herold-Mende C 2010. Rapid T-cell based identification of tissue antigens by automated two-dimensional protein fractionation. J Clin Invest 2010 Jun 1;120(6):2230-42. doi: 10.1172/JCI37646. Epub 2010 May 10.

Schmitz-Winnenthal F, Pietsch D, Schimmack S, Bonertz A, Udonta F, Ge Y, Galindo L, Volk C, Zgraggen K, Koch M, Buechler M, Weitz J, Beckhove, P. Chronic pancreatitis is associated with disease-specific regulatory T cell responses. Gastroenterology 2010 Mar;138(3):1178-88. Epub 2009 Nov 18.

Blatner NR, Bonertz A, Beckhove P, Cheon EC, Krantz SB, Strouch M, Weitz J, Koch M, Halverson AL, Bentrem DJ, Khazaie K. In colorectal cancer mast cells contribute to systemic regulatory T-cell dysfunction. Proc Natl Acad Sci U S A 2010 Apr 6;107(14):6430-5. Epub 2010 Mar 22.   

Schneider M, van Geyte K, Fraisl P, Kiss J, Aragones J, Mazzone M, Mairbäurl H, DeBock K, Jeoung N, Mollenhauer M, Georgiadou M, Bishop T, Roncal C, Sutherland A, Jordan B, Gallez B, Weitz J, Harris R, Maxwell P, Baes M, Ratcliffe P, Carmeliet P. Loss or silencing of the PHD1 Prolyl Hydroxylase protects livers of mice against ischemia/reperfusion injury. Gastroenterology 2010 Mar;138(3):1143-54.e1-2. Epub 2009 Oct 8.

Tambuwala MM, Cummins EP, Lenihan CR, Kiss J, Stauch M, Scholz CC, Fraisl P, Lasitschka F, Mollenhauer M, Saunders SP, Maxwell PH, Carmeliet P, Fallon PG, Schneider M1 and Taylor CT1Loss of prolyl hydroxylase-1 (PHD1) protects against colitis through reduced epithelial cell apoptosis and increased barrier function. Gastroenterology 2010 Dec;139(6):2093-101. Epub 2010 Jun 30. (1These authors contributed equally to this work)

2009

Bonertz A, Weitz J, Pietsch DH, Rahbari NN, Schlude C, Ge Y, Jünger S, Vlodavsky I +, Khazaie K, Jäger D, Reissfelder C, Antolovic D, Aigner M, Koch M, Beckhove P. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma.  J Clin Invest 2009 (11): 3311-21

Gounaris E, Blatner NR, Dennis K, Magnusson F, Gurish MF, Strom TB, Beckhove P, Gounari F, Khazaie K. T-regulatory cells shift from a protective anti-inflammatory to a cancer-promoting proinflammatory phenotype in polyposis. Cancer Res 2009 Jul 1;69(13):5490-7.

Khazaie K, Bonertz A, Beckhove P. Current developments with peptide-based human tumor vaccines. Curr Opin Oncol 2009 Nov;21(6):524-30. Review.